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ABSTRACT
OBJECTIVES The TRISCEND study (Edwards EVOQUE Tricuspid Valve Replacement: Investigation of Safety and Clinical
Efﬁcacy after Replacement of Tricuspid Valve with Transcatheter Device) is evaluating the safety and performance of
transfemoral transcatheter tricuspid valve replacement in patients with clinically signiﬁcant tricuspid regurgitation (TR)
and elevated surgical risk.
BACKGROUND Transcatheter valve replacement could lead to a paradigm shift in treating TR and improving patient
quality of life.
METHODS In the prospective, single-arm, multicenter TRISCEND study, patients with symptomatic moderate or greater
TR, despite medical therapy, underwent percutaneous transcatheter tricuspid valve replacement with the EVOQUE
system. A composite rate of major adverse events, echocardiographic parameters, and clinical, functional, and quality-oflife measures were assessed at 30 days.
RESULTS Fifty-six patients (mean age of 79.3 years, 76.8% female, 91.1% TR severe or greater, 91.1% atrial ﬁbrillation,
and 87.5% New York Heart Association functional class III or IV) were treated. At 30 days, TR was reduced to mild or less
in 98%. The composite major adverse events rate was 26.8% at 30 days caused by 1 cardiovascular death in a patient
with a failed procedure, 2 reinterventions after device embolization, 1 major access site or vascular complication, and 15
severe bleeds, of which none were life-threatening or fatal. No myocardial infarction, stroke, renal failure, major cardiac
structural complications, or device-related pulmonary embolism were observed. New York Heart Association signiﬁcantly
improved to functional class I or II (78.8%; P < 0.001), 6-minute walk distance improved 49.8 m (P < 0.001), and Kansas
City Cardiomyopathy Questionnaire score improved 19 points (P < 0.001).
CONCLUSIONS Early experience with the transfemoral EVOQUE system in patients with clinically signiﬁcant TR
demonstrated technical feasibility, acceptable safety, TR reduction, and symptomatic improvement at 30 days. The
TRISCEND II randomized trial (NCT04482062) is underway. (J Am Coll Cardiol Intv 2022;15:471–480) © 2022 Published
by Elsevier on behalf of the American College of Cardiology Foundation.
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PATIENT ELIGIBILITY. Patients at least 18 years of

age, with at least moderate functional or degenera-

F I G U R E 1 EVOQUE Tricuspid Valve Replacement System

tive TR despite medical therapy, were eligible for
enrollment. Medical therapy was at investigator
discretion and included diuretic medications in stable
doses unless a patient had a documented history of
intolerance.

Anticoagulation

was

recommended

through 6 months postprocedure.
Patients were excluded from the study if they had unsuitable anatomy for device placement, prior TV repair or

The EVOQUE valve design engages leaﬂets, chords, and annulus to achieve secure
placement. The valves (sized 44 mm, 48 mm, and 52 mm) are delivered by a 28-F
transfemoral delivery system.

replacement that would interfere with EVOQUE valve implantation, severe pulmonary hypertension (pulmonary
artery systolic pressure >70 mm Hg or >2/3 systemic with
pulmonary vascular resistance >5 WU after vasodilator
challenge), or severe RV dysfunction. Additional exclusion
criteria were left ventricular ejection fraction <25%, severe
renal insufﬁciency with estimated glomerular ﬁltration
rate #25 mL/min/1.73 m2 or requiring chronic renal
replacement therapy, along with comorbid condition(s)
that, in the opinion of the investigator, could limit patient
participation. Transthoracic echocardiography (TTE) images were recorded at baseline, discharge, and 30 days

capsule to ensure that anchors remain below the
leaﬂet tips and above the papillary muscle heads.
During further expansion, anchor tips are positioned
below the annulus and leaﬂets are captured. After
optimal anchor positioning and conﬁrmed leaﬂet
capture, the EVOQUE valve is fully deployed and
released from the delivery system. Finally, the delivery system is removed, and the femoral access site
is closed using standard techniques.

postprocedure. Transesophageal echocardiography (TEE)

ECHOCARDIOGRAPHIC

images were obtained at screening and intraprocedurally.

diograms were analyzed by the ECL following American

For pacemaker-dependent patients, a plan was made prior

Society of Echocardiography standards.16 Chamber size,

to the procedure for alternative pacing options, including a

function, and valvular regurgitation were assessed using

coronary sinus lead or a leadless pacemaker.

standard 2-dimensional color Doppler methods; TR

DEVICE AND PROCEDURE. The EVOQUE system uti-

lizes a transfemoral approach and consists of a 28-F
percutaneous delivery system (Figure 1) compatible
with all valve sizes; the EVOQUE valve implant

ASSESSMENT. All

echocar-

effective regurgitant oriﬁce and regurgitant volume were
quantiﬁed using the proximal isovelocity surface area
method.17,18 TR severity was graded using a prespeciﬁed
5-class scheme previously described.18-20

(Figure 1) in 44-mm, 48-mm, and 52-mm diameters; a

STUDY ENDPOINTS. The safety endpoint was a com-

loading system; and a dilator kit. The delivery system

posite rate of MAEs at 30 days postenrollment comprising

has 3 planes of motion, which allow steerability and

cardiovascular mortality; myocardial infarction; stroke;

precise positioning. Primary and secondary ﬂexion

renal complications requiring unplanned dialysis or renal

allow coaxial alignment with the TV, and depth of

replacement therapy; severe bleeding deﬁned as fatal,

implantation is adjustable with the depth knob.

life-threatening, extensive, or major bleeding according

The EVOQUE valve consists of a trileaﬂet bovine

to the Mitral Valve Academic Research Consortium21;

pericardial tissue valve, nitinol frame, and fabric

nonelective TV reintervention; major access site and

skirt. Nine anchors are positioned between the chor-

vascular complications; major cardiac structural compli-

dae tendineae to engage and capture native leaﬂets,

cations; and device-related pulmonary embolism.

while the valve frame and fabric skirt minimize the
risk of paravalvular leak (PVL).

Performance endpoints included device, procedural,
and clinical success. Device success was assessed at exit

Once femoral access is obtained, a pre-shaped

from the catheterization laboratory and deﬁned as device

guidewire is inserted into the right atrium (RA) and

deployed and delivery system retrieved as intended.

advanced across the TV into the RV with TEE guid-

Procedural success was evaluated based on device suc-

ance critical throughout the procedure. The delivery

cess at exit from the catheterization laboratory without

system is inserted over the guidewire and positioned

clinically signiﬁcant PVL on TTE at discharge, as assessed

at the junction of the inferior vena cava (IVC) and RA

by the ECL. Clinical success was deﬁned as procedural

before it is advanced and ﬂexed across the TV; the

success without any MAEs at 30 days. The echocardio-

delivery capsule is directed toward the RV and posi-

graphic endpoint was a reduction in TR grade from

tioned below the TV. After position and trajectory are

baseline to discharge. TR severity was assessed at base-

conﬁrmed, anchors are exposed by retracting the

line, discharge, and 30 days.
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F I G U R E 2 Patient Flowchart

T A B L E 1 Baseline Characteristics (N ¼ 56)

79.3  7.7

Age, y
Female

43 (76.8)

EuroSCORE II

5.6  4.9

STS score, mitral valve repair, %

7.7  5.3

NYHA functional class III or IV

49 (87.5)

Tricuspid valve pathology
Degenerative (primary)

6 (10.7)

Functional (secondary)

38 (67.9)

Mixed

10 (17.9)

Pacer related

1 (1.8)

Indeterminate

1 (1.8)

Comorbidities

Of the 56 enrolled patients, 53 had a 30-day follow-up visit.

Clinical, functional, and quality-of-life outcomes
(NYHA functional classiﬁcation, 6-minute walk dis-

Systemic hypertension (treated)

49 (87.5)

Pulmonary hypertension (sPAP $30 mm Hg)
in last 12 mo

45 (80.4)

Chronic obstructive pulmonary disease

10 (17.9)

Chronic kidney disease
(eGFR 15-89 mL/min/1.73 m2)

37 (66.1)

Diabetes

12 (21.4)

tance, Kansas City Cardiomyopathy Questionnaire)

Dyslipidemia or hyperlipidemia

39 (69.6)

were assessed at 30 days. Edema was assessed by

Ascites

12 (21.4)

patient questionnaire, ankle circumference mea-

Gastrointestinal or esophageal bleeding

11 (19.6)

surements, and a standard pitting grading scale.

Coronary artery disease ($50% stenosis)

8 (14.3)

Cerebrovascular disease (stroke or TIA)

15 (26.8)

STATISTICAL ANALYSIS. Analysis was performed

using SAS software version 9.4 (SAS Institute) and
represents the intent-to-treat population. Patients
with missing data were excluded from the denominator for endpoint calculations. For categorical data,
results were summarized with patient count, per-

Prior myocardial infarction

2 (3.6)

Prior percutaneous coronary intervention/stent

8 (14.3)

Peripheral arterial disease

1 (1.8)

Coronary artery bypass grafting

9 (16.1)

Prior carotid stenting/surgery

1 (1.8)

centage, and 95% CI by normal approximation, where

Prior valve surgery/intervention
(mitral/aortic/tricuspid)

appropriate. For continuous variables, results were

Atrial ﬁbrillation

51 (91.1)

summarized with the number of observations and

RBBB

11 (19.6)

mean  SD, and median (minimum, maximum) for

LBBB

6 (10.7)

hospital length of stay and 95% CI by normal

Pacemaker

19 (33.9)

approximation were also included. Comparative sta-

Prior heart failure hospitalization in last
12 months

20 (35.7)

tistics, including change from baseline to 30-day

22 (39.3)

Laboratory values

follow-up, were calculated with Wilcoxon signed

Albumin, g/dL

4.0  0.6

rank test or paired Student’s t-test.

Alanine transaminase, U/L

22.2  11.7

RESULTS
Fifty-six consecutive patients (76.8% women) (Figure 2)
with a mean age of 79.3  7.7 years were treated at 9 U.S.
investigational sites. Baseline clinical characteristics and
laboratory values are shown in Table 1. Patients were
deemed at high surgical risk with a mean Society of
Thoracic Surgeons score (mitral valve repair) of 7.7  5.3%

Aspartate transaminase, U/L

29.0  10.1

Alkaline phosphatase, U/L

115.7  62.5
86.5  76.3

Gamma-glutamyltransferase, U/L
B-type natriuretic peptide

678.8  1,813.8

Prothrombin time, s

18.8  8.2

INR

1.6  0.74

eGFR, mL/min/1.73 m2

49.0  12.9

Creatinine, mg/dL

1.2  0.3

Uric acid, mg/dL

7.4  2.9

and a EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) of 5.6  4.9%. A total of 91.1%
presented with torrential, massive, or severe TR; most
had functional TR (67.9%).
Most patients were in NYHA functional class III or

Values are mean  SD or n (%).
eGFR ¼ estimated glomerular ﬁltration rate; EuroSCORE ¼ European System for
Cardiac Operative Risk Evaluation; INR ¼ international normalized ratio;
LBBB ¼ left bundle branch block; NYHA ¼ New York Heart Association;
RBBB ¼ right bundle branch block; sPAP ¼ systolic pulmonary artery pressure;
STS ¼ The Society of Thoracic Surgeons; TIA ¼ transient ischemic attack.

IV (87.5%). Major comorbidities included atrial
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T A B L E 2 Procedural Characteristics and Clinical Success (N ¼ 56)

Right femoral vein access

56/56 (100)

Device successa

55/56 (98.2)

Procedural successb

54/56 (96.4)

c

41/56 (73.2)

Clinical success

Device time (implant insertion to release), min

70.1  31.5 (56)

Fluoroscopy time, min

32.6  14.3 (56)

Hospital length of stay, d
Mean  SD (n)

4.3  4.3 (56)

Median (range)

3.0 (1.0-25.0)d

95% CI

3.2-5.5

T A B L E 3 TR Grade at Baseline and Discharge

TR severity
0 ¼ none/trace
01 ¼ mild
02 ¼ moderate
03 ¼ severe
04 ¼ massive
05 ¼ torrential

Baseline

Discharge

0/55 (0)
0/55 (0)
5/55 (9.1)
25/55 (45.5)
15/55(27.3)
10/55 (18.2)

35/55 (64)
18/55 (33)
2/55 (4)
0/55 (0)
0/55 (0)
0/55 (0)

P Value, Baseline
vs Dischargea

<0.001

Values are n/N (%). aP value by Wilcoxon signed rank test comparing baseline with
discharge.
TR ¼ tricuspid regurgitation.

Discharge location
Home

48/56 (85.7)

Home with services

4/56 (7.1)

Skilled nursing facility

2/56 (3.6)

Other hospital

1/56 (1.8)

53 completed 30-day follow-up (Figure 2). Clinical

Other

1/56 (1.8)

success occurred in 73.2%. The 30-day MAEs adjudi-

30-DAY CLINICAL OUTCOMES. Of enrolled patients,

cated by the clinical events committee are shown in
Values are n/N (%) or mean  SD (n), unless otherwise indicated. aDevice is
deployed and delivery system successfully retrieved as intended at the time of the
patient’s exit from the cardiac catheterization laboratory. bDevice success and no
clinically signiﬁcant paravalvular leak on transthoracic echocardiogram (assessed
by the echocardiographic core laboratory) at the time of discharge. cProcedural
success and no MAEs at 30 days. dOne patient required 25 days of hospitalization
caused by valve embolization, subsequent emergent redo sternotomy, and notable
post-surgical bleeding from the chest tube.

Table 4. Fifteen (26.8%) patients experienced MAEs,
with 1 cardiovascular death (1.8%), 2 nonelective TV
reinterventions, 1 major access site or vascular
complication, and 15 severe bleeding events (none
life-threatening or fatal). No myocardial infarction,
stroke, renal failure requiring dialysis, major cardiac

ﬁbrillation (91.1%), systemic hypertension (87.5%),
and pulmonary hypertension (80.4%).
Prior cardiac treatments included valve surgery or
intervention (39.3%) and pacemaker or implantable
cardioverter-deﬁbrillator implantation (33.9%) with
leads crossing the TV annulus in 32%. Heart failure
hospitalization occurred in 35.7% within 12 months
prior to enrollment, and 35.7% reported ankle swelling
with a moderate to extreme impact on activity level.
Baseline RV function assessment demonstrated a
mean tricuspid annular plane systolic excursion of
14.6  4.2 mm and RV fractional area change of
37.1  9.2%. Effective regurgitant oriﬁce area was 0.76
 0.56 cm2 , regurgitant volume was 55.1  29.4 mL,
and

vena

contracta

width

measured

via

2-dimensional TTE RV inﬂow or apical 4-chamber
view was 8.7  3.2 mm or 10.0  4.3 mm, respectively.

structural complications, or device-related pulmonary embolism were observed.
The all-cause 30-day mortality rate was 3.6%
(n ¼ 2). These 2 deaths included the previously
mentioned cardiovascular mortality and 1 noncardiovascular death in a patient who died from
carcinoid syndrome in hospital. The cardiovascular
death was related to the device and procedure and
occurred in an 82-year-old patient with a history of
congestive heart failure (NYHA functional class III at
baseline). Intraprocedure TEE conﬁrmed that the
implant migrated, resulting in severe TR and moderate PVL. The patient underwent valve-in-valve implantation during the index procedure, did not
improve clinically, and died of heart failure and RV
dysfunction 20 days postprocedure.
Nonelective TV reinterventions occurred in 1 patient on postoperative day 1 (before discharge, partial

ACUTE CLINICAL OUTCOMES. All patients received

embolization) and in another patient on day 2 (after

an EVOQUE valve via right femoral vein access with a

discharge, embolization); both underwent surgical

mean implantation time of 70.1  31.5 minutes. Median

reintervention with a bioprosthetic valve. The severe

hospital length of stay postprocedure was 3 days

bleeding events were extensive (n ¼ 7) and major

(range: 1-25 days), and 92.9% were discharged directly

(n ¼ 8); none were life-threatening or fatal (Table 4).

home. Device success was achieved in 98.2% and

They included 3 access site, 2 epistaxes, 3 gastroin-

procedural success was achieved in 96.4% (Table 2).

testinal, 1 hematuria, 1 hemolytic anemia in a patient

At discharge, 100% of patients had a reduction of 1

with a history of anemia of chronic disease, 2 peri-

TR grade or more, and 98.1% showed an improvement

operative blood losses during surgical tricuspid rein-

of 2 or more grades. Overall, the reduction in TR

tervention, and 3 vascular (nonaccess site) bleeds.

severity by discharge showed signiﬁcant improve-

Nine of these patients required transfusion of at least

ment (P < 0.001) (Table 3).

1 unit of packed red blood cells. All patients who
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T A B L E 4 Clinical Events Committee–Adjudicated Safety Events at 30 Days

(N ¼ 56)

1 (1.8)a

Cardiovascular mortality
Myocardial infarction

0

Stroke

0

Renal complications requiring dialysis or renal replacement therapy

0

New need for renal replacement therapy

0

Severe bleedingb

15 (26.8)

Fatal

0

Life-threatening

0

Extensive

7 (12.5)

Major

8 (14.3)

Nonelective tricuspid valve reintervention

2 (3.6)

Major access site and vascular complications requiring intervention

1 (1.8)

Major cardiac structural complications

0

Device-related pulmonary embolism

0

Composite MAE rate

15 (26.8)

Values are as n (%) or n. aAll-cause mortality included 1 cardiovascular and 1 noncardiovascular
death. bSevere bleeding is deﬁned as major, extensive, life-threatening, or fatal bleeding per
Mitral Valve Academic Research Consortium criteria.

experienced MAE bleeds were on anticoagulation or
antiplatelet medication before the procedure; 73%
were taking warfarin. Of 36 patients without a pacemaker prior to enrollment, 4 (11.1%) developed new
conduction disturbances requiring permanent pacemaker implantation (site reported).
Clinical, functional, and quality-of-life outcomes
signiﬁcantly improved at 30 days (Central Illustration).
Most patients (87.5%) were in NYHA functional class III or
IV at baseline, and at 30 days, 78.8% were in NYHA functional class I or II (P < 0.001). The 6-minute walk distance
increased a mean of 49.8  80.5 m at 30 days (P < 0.001)
from 199.1  128.6 m at baseline to 248.9  127.5 m. The
City

artery systolic pressure decreased from 40.1 
10.5 mm Hg to 32.2  10.2 mm Hg (P ¼ 0.002). Mean
gradient was 3.4  1.5 mm Hg at 30 days (Table 5).
Measures of right heart remodeling showed signiﬁcant improvement at 30 days. RV end-diastolic
and end-systolic areas signiﬁcantly improved from
33.1  7.2 cm 2 to 23.4  7.1 cm 2 (P < 0.001) and from
20.5  5.1 cm 2 to 17.6  5.8 cm 2 (P ¼ 0.001), respectively, and IVC diameter (expiration) reduced from
27.0  7.1 mm to 21.3  5.6 mm (P < 0.001). There was
worsening of RV function between baseline and
30 days by tricuspid annular plane systolic excursion
(14.9  3.9 mm vs 13.0  3.19 mm; P ¼ 0.035) and RV
fractional area change (37.6  9.3% to 24.8  9.9%;
P < 0.001). RA systolic volume decreased from 154.1 
66.1 mL to 138.2  61.8 mL (P ¼ 0.009). Left ventricular ejection fraction signiﬁcantly improved from
53.4  10.2% to 58.2  10.4% (P ¼ 0.014).

DISCUSSION

MAE ¼ major adverse event(s).

Kansas

improved by 2 or more grades (Figure 3). Pulmonary

Cardiomyopathy

Questionnaire

score

improved from 46.5  23.1 points at baseline to 65.6  21.6
points, a mean improvement of 19.0  20.5 points at
30 days (P < 0.001). Edema assessed by standard pitting
test signiﬁcantly improved at 30 days (P < 0.001), and
13.7% reported ankle swelling with moderate to extreme
activity limitations at 30 days compared with 35.7% at
baseline. Ankle circumference improved (left: from 23.0 
3.8 cm to 21.8  4.6 cm; P ¼ 0.003; right: from 23.1  3.7 cm
to 21.9  4.5 cm; P ¼ 0.002), and body weight decreased
(from 73.7  18.6 kg to 71.6  19.4 kg; P ¼ 0.008).

Here, we report initial results from the ongoing
TRISCEND study, which is evaluating feasibility and
safety of transfemoral TTVR with the EVOQUE system
in patients with at least moderate TR. We saw high
rates of device and procedural success (98.2% and
96.4%, respectively), with low mortality and signiﬁcant TR reduction. Importantly, these acute outcomes
were associated with signiﬁcant improvements in
functional status and quality of life at 30 days.
Current guidelines do not recommend surgery for
isolated TR.22,23 Most studies have demonstrated high
surgical mortality of 9% to 11%,8,24-26 with limited
single-site reports showing lower in-hospital mortality between 3.1% and 3.7% for isolated TR redo surgery

using

minimally

techniques. 27-29

invasive

Results with a percutaneous transcatheter approach
in the TRISCEND study compare favorably with an inhospital mortality of 1.8% and a 30-day MAE rate of
26.8% in a more complex, high-surgical-risk patient
population

with

advanced

age

and

signiﬁcant

comorbidities. These results also compare favorably
to the only other published series of TTVR, which
utilized surgical cutdown and a transatrial approach
in most patients and demonstrated signiﬁcant TR
reduction and symptomatic improvement but higher

30-DAY TTE RESULTS. At baseline, TR severity was

in-hospital mortality of 10%. 16 The lower mortality in

torrential (15.4%), massive (25.0%), severe (50.0%), or

the TRISCEND study is potentially caused by the

moderate (9.6%), which reduced to none or trace or

percutaneous transfemoral approach.

mild TR in 98.1% at 30 days (P < 0.001) (Central

Multiple lower-risk transcatheter treatment op-

Illustration). At 30 days, 100% of patients had a

tions for patients with symptomatic severe TR have

reduction of one TR grade or more, and 98.1%

recently been evaluated. 11,13,30 The most robust early
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C ENTR AL I LL U STRA T I O N 30-Day Results of the TRISCEND Study With the EVOQUE System

A

B

TR Severity
100

P < 0.001
1.9%

NYHA
P < 0.001
100

15.4%

IV

III

25.0%
80
25.0%
60
98.1%

40
50.0%

73.1%

NYHA - Patients (%)

TR Severity - Patients (%)

80

20

0

III
II
40

II

9.6%

0

Baseline 30 Days
n = 52
Massive

Severe

6MWD

Moderate

D

Baseline 30 Days
n = 52
Mild

None/Trace

P < 0.001
Δ = 19.0 pts

300

80
248.9
± 127.5

250
199.1
± 128.6

150

100

65.6
± 21.6

70

KCCQ - Overall Score

6MWD - Distance Walked (m)

I

KCCQ

P < 0.001
Δ = 49.8m

200

78.8%

20

Torrential

C

60

60
50

46.5
± 23.1

40
30
20

50

0

10
Baseline 30 Days
n = 46

0

Baseline 30 Days
n = 51

Kodali, S. et al. J Am Coll Cardiol Intv. 2022;15(5):471–480.

Transfemoral tricuspid valve replacement with the EVOQUE system showed reduced tricuspid regurgitation (TR) severity and improved
clinical, functional, and quality-of-life outcomes. (A) The Baylor Scott and White Research Institute core laboratory assessed TR severity.
P value from Wilcoxon signed rank test. (B) P value from Wilcoxon signed rank test. (C) P value from paired Student’s t-test. (D) P value from
paired Student’s t-test. Values are mean  SD. 6MWD ¼ 6-minute walk distance; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire;
NYHA ¼ New York Heart Association; TRISCEND ¼ Edwards EVOQUE Tricuspid Valve Replacement: Investigation of Safety and Clinical
Efﬁcacy after Replacement of Tricuspid Valve with Transcatheter Device.
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feasibility data comes from 2 studies of transcatheter

F I G U R E 3 Reduced Severity of TR at 30 Days

edge-to-edge repair with either the PASCAL transcatheter valve repair system (Edwards Lifesciences) 13
or

the

TriClip

transcatheter

TV

repair

system

(Abbott).31 These studies demonstrated safety and
technical feasibility of these approaches, with significant reduction in TR and clinical improvement.
However, they also highlighted technical challenges,
including inadequate leaﬂet imaging, inability to
treat large coaptation gaps, and interference of device
placement by pacemaker leads. An analysis of transcatheter edge-to-edge repair patients in a TV repair
registry (TriValve) demonstrated substantial residual
TR, with 64% still experiencing moderate or greater
TR at last follow-up (mean 290 days), potentially
leading to worse long-term outcomes.32 In addition,
although infrequent, single leaﬂet detachments can
occur, leading to recurrence of TR.
One challenge with transcatheter replacement is
adequate anchoring given the asymmetric nature of the
tricuspid annulus and lack of calcium. The EVOQUE system relies both on leaﬂet capture and annular oversizing
for adequate ﬁxation. Device embolization is a potentially
catastrophic complication. In this study, there were 2
cases of device embolization (3.6%) and 1 device migration (1.8%) requiring reintervention. The cause of these
embolizations is unclear, although a combination of factors (such as sizing and procedural considerations) likely
contributed; further study is required to reﬁne patient
selection and procedural technique to reduce the incidence and improve device success.
Another concern with valve replacement is the ability
All patients with available data (n ¼ 52) had at least 1 grade reduction, and 98.1% had at

of the RV to tolerate TR elimination, as it may increase RV

least 2 grades’ reduction in tricuspid regurgitation (TR) severity between baseline and

afterload and lead to RV failure. Although quantitative

30 days.

measures showed some reduction in RV function post
TTVR in this study, there was no clinical evidence of RV
failure at 30 days despite 45% of patients having massive
or torrential TR, except in the previously mentioned
cardiovascular mortality caused by heart failure and RV

T A B L E 5 Paired Baseline and 30-Day Follow-Up Echocardiographic Parameters

n

Baseline

30 d

P Valuea

PASP, mm Hg

31

40.1  10.5

32.2  10.2

0.002b

RV end-diastolic area, cm2

45

33.1  7.2

23.4  7.1

<0.001b

RV end-systolic area, cm2

45

20.5  5.1

17.6  5.8

0.001b

RV FAC, %

45

37.6  9.3

24.8  9.9

<0.001b

IVC diameter, expiration, mm

48

27.0  7.1

21.3  5.6

<0.001b

RA volume systolic, mL

52

154.1  66.1

138.2  61.8

0.009b

TAPSE, mm

24

14.9  3.9

13.0  3.2

0.035b

TV mean gradient, mm Hg

49

1.8  1.1

3.4  1.5

<0.001b

LVEF, %

47

53.4  10.2

58.2  10.4

0.014b

a

b

Values are mean  SD. P values calculated by Student’s t-test for paired analysis. Statistically signiﬁcant.
FAC ¼ fractional area change; IVC ¼ inferior vena cava; LVEF ¼ left ventricular ejection fraction;
PASP ¼ pulmonary artery systolic pressure; RA ¼ right atrial; RV ¼ right ventricular; TAPSE ¼ tricuspid annular
plane systolic excursion; TV ¼ tricuspid valve.

dysfunction after an unsuccessful procedure. Whether RV
function will return to baseline or even improve at longerterm follow-up remains to be seen. While there are limitations to quantifying and interpreting RV function, and
despite it appearing to slightly worsen at 30 days, there
were positive signs of RV remodeling with a reduction of
RV, RA, and IVC dimensions in the TRISCEND study.
Another recent study showed that after isolated TV
intervention, patients who exhibited RV reverse remodeling (reduction in RV size with no more than mild RV
dysfunction) within 18 months postoperatively had
signiﬁcantly improved survival.33
In the TRISCEND study, the MAE rate was primarily
driven by severe bleeding events. Importantly, none
were life-threatening or fatal, and the majority were
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not access site or device related. Many of these events
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CONCLUSIONS
Symptomatic, signiﬁcant TR is currently undertreated, TV surgery carries high risks, and conserva-

PERSPECTIVES

tive medical therapy has unsatisfactory outcomes.
Early experience with the transfemoral EVOQUE TV

WHAT IS KNOWN? Clinically relevant TR is frequently under-

replacement system in the TRISCEND study shows

treated and associated with reduced quality of life and increased

safety and favorable performance, with a signiﬁcant

mortality. Transcatheter treatment options may be safe and

reduction in TR severity and associated improve-

improve long-term patient outcomes, and are being evaluated.

ments in clinical, functional, and quality-of-life
measures. The EVOQUE system could provide an

WHAT IS NEW? Thirty-day results of the TRISCEND study show

attractive alternative to surgery or conservative

promising safety and high procedural success with a percuta-

medical therapy for reduction of TR severity and

neous transcatheter valve replacement using the EVOQUE sys-

improvement in patient outcomes. The TRISCEND

tem. Patients had signiﬁcant improvements in TR, NYHA

study is ongoing, and a randomized pivotal trial (the

functional class, 6-minute walk distance, and quality of life at

TRISCEND II study [NCT04482062]) has commenced.

30 days.
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